ceftriaxone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 564 73384-59-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ceftriaxone sodium hydrate
  • ceftriaxone
  • biotrakson
  • rocefin
  • rocephalin
  • rophex
  • ceftriaxone sodium
A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.
  • Molecular weight: 554.57
  • Formula: C18H18N8O7S3
  • CLOGP: 0.02
  • LIPINSKI: 2
  • HAC: 15
  • HDO: 4
  • TPSA: 208.98
  • ALOGS: -3.72
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g P
2 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 400 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 46 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 120.27 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.22 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 1984 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 530.27 11.77 312 35460 29236 46621054
Toxic epidermal necrolysis 312.21 11.77 201 35571 22077 46628213
Acute generalised exanthematous pustulosis 270.97 11.77 136 35636 9269 46641021
Acute kidney injury 244.78 11.77 550 35222 235305 46414985
Pseudocholelithiasis 197.61 11.77 32 35740 0 46650290
Jarisch-Herxheimer reaction 190.96 11.77 45 35727 267 46650023
Rash maculo-papular 181.81 11.77 159 35613 27715 46622575
Eosinophilia 176.84 11.77 134 35638 19083 46631207
Recalled product administered 175.83 11.77 40 35732 198 46650092
Multiple organ dysfunction syndrome 165.40 11.77 201 35571 51509 46598781
Fatigue 160.64 11.77 139 35633 608558 46041732
Pyrexia 158.99 11.77 606 35166 348196 46302094
Agranulocytosis 157.80 11.77 133 35639 22052 46628238
Rheumatoid arthritis 154.61 11.77 7 35765 240208 46410082
Hepatitis 143.77 11.77 149 35623 32066 46618224
Haemolytic anaemia 133.39 11.77 87 35685 9755 46640535
Cholelithiasis 129.63 11.77 154 35618 38527 46611763
Septic shock 129.60 11.77 189 35583 57704 46592586
Factor V inhibition 128.42 11.77 29 35743 138 46650152
Stevens-Johnson syndrome 122.85 11.77 118 35654 23179 46627111
Anaphylactic shock 119.02 11.77 109 35663 20165 46630125
Postrenal failure 109.95 11.77 23 35749 70 46650220
Clostridium difficile colitis 109.40 11.77 100 35672 18453 46631837
Pain 108.25 11.77 124 35648 476824 46173466
Tubulointerstitial nephritis 105.85 11.77 89 35683 14699 46635591
Hepatocellular injury 102.99 11.77 120 35652 29402 46620888
Electrocardiogram QT prolonged 101.25 11.77 158 35614 51167 46599123
Joint swelling 97.32 11.77 8 35764 166065 46484225
Cholestasis 96.64 11.77 111 35661 26782 46623508
Headache 92.51 11.77 140 35632 478212 46172078
Fall 89.12 11.77 73 35699 329024 46321266
Drug interaction 88.21 11.77 348 35424 202746 46447544
Product dose omission issue 86.47 11.77 13 35759 168507 46481783
Arthralgia 83.46 11.77 94 35678 364509 46285781
Drug intolerance 78.60 11.77 10 35762 147039 46503251
Pseudomembranous colitis 77.02 11.77 41 35731 3154 46647136
Status epilepticus 74.05 11.77 71 35701 13908 46636382
Leukocytosis 70.00 11.77 88 35684 23310 46626980
Haemophagocytic lymphohistiocytosis 67.66 11.77 54 35718 8288 46642002
Premature delivery 67.62 11.77 84 35688 21985 46628305
Alopecia 66.23 11.77 21 35751 162393 46487897
Weight increased 65.78 11.77 22 35750 164451 46485839
Off label use 64.99 11.77 505 35267 379336 46270954
Erythema 62.15 11.77 245 35527 142575 46507715
Choreoathetosis 61.91 11.77 20 35752 422 46649868
Long QT syndrome 61.76 11.77 35 35737 3045 46647245
Enterococcal infection 60.48 11.77 47 35725 6940 46643350
Pain in extremity 59.88 11.77 66 35706 258614 46391676
Respiratory failure 59.81 11.77 184 35588 94632 46555658
Toxic encephalopathy 59.58 11.77 41 35731 5021 46645269
Thrombocytopenia 59.04 11.77 222 35550 126359 46523931
Linear IgA disease 58.67 11.77 26 35746 1335 46648955
Acute respiratory distress syndrome 58.62 11.77 78 35694 21844 46628446
Sepsis 58.11 11.77 232 35540 135782 46514508
Injection site pain 57.95 11.77 7 35765 107145 46543145
Abdominal discomfort 57.41 11.77 22 35750 151143 46499147
Myasthenia gravis crisis 56.58 11.77 18 35754 361 46649929
Altered state of consciousness 56.27 11.77 79 35693 23269 46627021
Encephalopathy 56.18 11.77 96 35676 33493 46616797
Dizziness 56.18 11.77 110 35662 340304 46309986
Hepatitis cholestatic 55.82 11.77 44 35728 6633 46643657
Clostridium difficile infection 54.75 11.77 81 35691 25022 46625268
Symmetrical drug-related intertriginous and flexural exanthema 53.10 11.77 16 35756 266 46650024
Arthropathy 52.73 11.77 3 35769 84697 46565593
Insomnia 51.94 11.77 31 35741 164893 46485397
Nasopharyngitis 51.29 11.77 27 35745 153971 46496319
Urticaria 51.07 11.77 202 35570 117690 46532600
Drug-induced liver injury 49.87 11.77 78 35694 25290 46625000
Dermatitis exfoliative 48.50 11.77 38 35734 5678 46644612
Pneumococcal infection 47.83 11.77 16 35756 378 46649912
Transaminases increased 45.97 11.77 79 35693 27682 46622608
Nausea 45.87 11.77 324 35448 687130 45963160
Neutropenia 45.77 11.77 224 35548 142980 46507310
Psoriasis 45.43 11.77 4 35768 78600 46571690
Peripheral swelling 45.32 11.77 33 35739 158038 46492252
Acinetobacter infection 45.21 11.77 22 35750 1400 46648890
Tachypnoea 44.56 11.77 55 35717 14296 46635994
Rash morbilliform 44.23 11.77 28 35744 2981 46647309
Red man syndrome 43.28 11.77 20 35752 1133 46649157
Therapeutic product effect decreased 43.20 11.77 6 35766 82595 46567695
Tachycardia 42.57 11.77 170 35602 99452 46550838
Cholangitis 41.67 11.77 32 35740 4642 46645648
Klebsiella infection 41.41 11.77 37 35735 6625 46643665
Pancytopenia 41.15 11.77 151 35621 84907 46565383
Cholecystitis 41.04 11.77 53 35719 14413 46635877
Depression 40.88 11.77 42 35730 170062 46480228
Cardiac arrest 40.85 11.77 157 35615 90242 46560048
Hypoxia 40.82 11.77 109 35663 51729 46598561
Muscle spasms 40.38 11.77 22 35750 123091 46527199
Haemolysis 40.36 11.77 35 35737 6024 46644266
Malaise 39.80 11.77 126 35646 331106 46319184
Bronchopulmonary aspergillosis 39.56 11.77 38 35734 7458 46642832
Acute respiratory failure 39.46 11.77 76 35696 29062 46621228
Pyuria 38.31 11.77 21 35751 1712 46648578
Gait disturbance 38.27 11.77 33 35739 145230 46505060
Rash 38.15 11.77 429 35343 356083 46294207
Drug resistance 37.81 11.77 56 35716 17312 46632978
Swelling 36.99 11.77 25 35747 124486 46525804
Death 36.66 11.77 133 35639 335415 46314875
Pathogen resistance 36.37 11.77 33 35739 6027 46644263
Hypertransaminasaemia 35.83 11.77 26 35746 3462 46646828
Weight decreased 35.71 11.77 67 35705 210782 46439508
Low birth weight baby 35.41 11.77 31 35741 5403 46644887
Injection site erythema 35.38 11.77 7 35765 74420 46575870
Stenotrophomonas infection 34.08 11.77 19 35753 1601 46648689
Maternal exposure during pregnancy 33.89 11.77 162 35610 102387 46547903
Influenza B virus test positive 33.36 11.77 12 35760 354 46649936
Contraindicated product administered 33.17 11.77 10 35762 79937 46570353
Pleocytosis 32.76 11.77 13 35759 505 46649785
Contusion 32.75 11.77 13 35759 87474 46562816
CSF measles antibody positive 32.68 11.77 8 35764 57 46650233
Laryngeal stenosis 32.40 11.77 14 35758 676 46649614
Hydronephrosis 31.92 11.77 36 35736 8509 46641781
Leukaemoid reaction 31.89 11.77 10 35762 191 46650099
Rubella antibody positive 31.87 11.77 8 35764 64 46650226
Product use in unapproved indication 31.58 11.77 145 35627 90128 46560162
Anaphylactic reaction 31.56 11.77 101 35671 53011 46597279
Alveolitis 31.11 11.77 21 35751 2492 46647798
Toxicity to various agents 31.06 11.77 73 35699 211693 46438597
COVID-19 pneumonia 30.47 11.77 23 35749 3252 46647038
Meningitis bacterial 30.30 11.77 16 35756 1210 46649080
Exposure during pregnancy 30.18 11.77 163 35609 108049 46542241
Dermatitis bullous 29.92 11.77 33 35739 7610 46642680
Lip oedema 29.92 11.77 23 35749 3341 46646949
Blood pressure increased 29.61 11.77 32 35740 126634 46523656
Blood brain barrier defect 29.26 11.77 8 35764 92 46650198
Torsade de pointes 29.10 11.77 41 35731 12113 46638177
Intentional overdose 29.06 11.77 7 35765 64937 46585353
Feeling abnormal 28.78 11.77 32 35740 125028 46525262
Nosocomial infection 28.59 11.77 17 35755 1618 46648672
Bile duct stone 27.17 11.77 22 35750 3445 46646845
Myocardial infarction 27.11 11.77 21 35751 97507 46552783
No adverse event 26.97 11.77 72 35700 34159 46616131
Migraine 26.88 11.77 10 35762 70016 46580274
Premature baby 26.71 11.77 49 35723 18063 46632227
Arthritis 26.56 11.77 13 35759 77303 46572987
Renal failure 26.39 11.77 163 35609 113431 46536859
Enterobacter infection 26.35 11.77 17 35755 1870 46648420
CSF protein increased 26.13 11.77 11 35761 498 46649792
Musculoskeletal stiffness 26.12 11.77 22 35750 97971 46552319
Gastroenteritis clostridial 26.08 11.77 11 35761 500 46649790
Respiratory distress 26.02 11.77 68 35704 31848 46618442
Guillain-Barre syndrome 25.87 11.77 21 35751 3301 46646989
Pelvic inflammatory disease 25.74 11.77 16 35756 1650 46648640
Thunderclap headache 25.65 11.77 8 35764 150 46650140
Bacteriuria 25.56 11.77 12 35760 705 46649585
Encephalitis 25.50 11.77 30 35742 7418 46642872
Weber tuning fork test abnormal 25.33 11.77 7 35765 84 46650206
Osteoarthritis 25.29 11.77 8 35764 62017 46588273
Autoimmune haemolytic anaemia 25.19 11.77 23 35749 4235 46646055
Organic brain syndrome 25.12 11.77 8 35764 161 46650129
Metabolic acidosis 25.12 11.77 76 35696 38704 46611586
Leukopenia 24.81 11.77 111 35661 68232 46582058
Factor V deficiency 24.54 11.77 7 35765 95 46650195
Hepatitis infectious mononucleosis 24.48 11.77 7 35765 96 46650194
Pneumonia 24.32 11.77 414 35358 375906 46274384
International normalised ratio increased 24.17 11.77 85 35687 46798 46603492
Clostridium colitis 23.95 11.77 16 35756 1866 46648424
Pyelonephritis acute 23.81 11.77 22 35750 4112 46646178
Glossodynia 23.73 11.77 3 35769 44370 46605920
Eosinophilic pneumonia 23.48 11.77 16 35756 1928 46648362
Cyanosis 23.29 11.77 43 35729 15928 46634362
Alanine aminotransferase increased 23.16 11.77 131 35641 88320 46561970
Cardiogenic shock 22.51 11.77 43 35729 16341 46633949
Back pain 22.40 11.77 84 35688 209955 46440335
Systemic lupus erythematosus 22.32 11.77 11 35761 65169 46585121
Haemostasis 22.18 11.77 8 35764 238 46650052
Pemphigus 22.06 11.77 4 35768 45270 46605020
Abdominal wall haematoma 21.98 11.77 18 35754 2863 46647427
Meningism 21.95 11.77 9 35763 381 46649909
Renal papillary necrosis 21.89 11.77 8 35764 247 46650043
Suicidal ideation 21.73 11.77 8 35764 56374 46593916
SJS-TEN overlap 21.57 11.77 7 35765 150 46650140
Shock 21.47 11.77 50 35722 21795 46628495
Abdominal pain upper 21.36 11.77 50 35722 145255 46505035
Drug abuse 21.27 11.77 11 35761 63397 46586893
Pruritus 21.23 11.77 281 35491 242071 46408219
Intravascular haemolysis 21.11 11.77 8 35764 274 46650016
Angioedema 20.86 11.77 72 35700 39270 46611020
Dry mouth 20.82 11.77 8 35764 54918 46595372
Inappropriate schedule of product administration 20.75 11.77 12 35760 65001 46585289
Hyporesponsive to stimuli 20.58 11.77 11 35761 853 46649437
Cholangitis acute 20.51 11.77 9 35763 451 46649839
Veillonella infection 20.50 11.77 5 35767 35 46650255
Hepatosplenomegaly 20.40 11.77 16 35756 2394 46647896
Morganella infection 20.33 11.77 9 35763 461 46649829
Palpitations 20.18 11.77 26 35746 95233 46555057
Rash erythematous 20.11 11.77 65 35707 34285 46616005
Neurotoxicity 20.09 11.77 37 35735 13680 46636610
Acquired haemophilia 19.81 11.77 11 35761 920 46649370
Pneumonia necrotising 19.66 11.77 8 35764 332 46649958
Aspartate aminotransferase increased 19.58 11.77 115 35657 78585 46571705
Anuria 19.54 11.77 33 35739 11398 46638892
Aspergillus infection 19.16 11.77 25 35747 6865 46643425
Encephalitis brain stem 19.16 11.77 6 35766 114 46650176
Haemodialysis 19.03 11.77 29 35743 9188 46641102
Drug eruption 19.01 11.77 47 35725 21282 46629008
Infantile apnoea 18.82 11.77 10 35762 766 46649524
Cerebral artery stenosis 18.82 11.77 8 35764 371 46649919
Oliguria 18.71 11.77 28 35744 8731 46641559
Coagulation factor deficiency 18.69 11.77 4 35768 14 46650276
Postpartum sepsis 18.69 11.77 4 35768 14 46650276
Anxiety 18.61 11.77 74 35698 181883 46468407
Bronchopleural fistula 18.60 11.77 7 35765 235 46650055
Blood creatinine increased 18.60 11.77 111 35661 76292 46573998
Anti factor V antibody 18.53 11.77 3 35769 0 46650290
Antibiotic associated colitis 18.53 11.77 3 35769 0 46650290
Coagulation factor decreased 18.49 11.77 5 35767 55 46650235
Hospitalisation 18.45 11.77 13 35759 63372 46586918
Hypofibrinogenaemia 18.38 11.77 11 35761 1059 46649231
Hypercreatininaemia 18.33 11.77 8 35764 396 46649894
Cataract 18.26 11.77 6 35766 45409 46604881
Gastrooesophageal reflux disease 18.25 11.77 18 35754 74326 46575964
Meningitis 18.22 11.77 23 35749 6113 46644177
Mobility decreased 18.21 11.77 12 35760 60582 46589708
Respiratory acidosis 18.19 11.77 23 35749 6125 46644165
Multiple sclerosis relapse 17.96 11.77 5 35767 42120 46608170
Cholestatic liver injury 17.96 11.77 14 35758 2076 46648214
Face oedema 17.91 11.77 43 35729 19110 46631180
Erythema multiforme 17.91 11.77 29 35743 9675 46640615
Encephalitis autoimmune 17.88 11.77 11 35761 1113 46649177
Foetal exposure during pregnancy 17.83 11.77 58 35714 30689 46619601
Hypertension 17.56 11.77 84 35688 196272 46454018
Memory impairment 17.56 11.77 20 35752 77317 46572973
Jaundice 17.26 11.77 55 35717 28790 46621500
Hypokalaemia 17.21 11.77 121 35651 87903 46562387
Unresponsive to stimuli 17.16 11.77 59 35713 32115 46618175
Fibrin D dimer increased 17.04 11.77 18 35754 3955 46646335
Inflammatory marker increased 17.02 11.77 21 35751 5454 46644836
Asymptomatic bacteriuria 16.95 11.77 5 35767 77 46650213
Pseudophaeochromocytoma 16.95 11.77 5 35767 77 46650213
Hypotension 16.89 11.77 261 35511 232328 46417962
Nasal congestion 16.65 11.77 8 35764 48105 46602185
Wound 16.62 11.77 6 35766 42796 46607494
Influenza like illness 16.50 11.77 12 35760 57558 46592732
Red blood cell agglutination 16.45 11.77 3 35769 3 46650287
Hyperthermia malignant 16.35 11.77 9 35763 740 46649550
Bronchial obstruction 16.25 11.77 11 35761 1311 46648979
Relapsing fever 16.19 11.77 6 35766 193 46650097
Musculoskeletal pain 16.07 11.77 18 35754 70110 46580180
Disseminated intravascular coagulation 16.01 11.77 41 35731 18964 46631326
Erythema nodosum 15.96 11.77 17 35755 3769 46646521
Stomatococcal infection 15.87 11.77 5 35767 97 46650193
Haemoperitoneum 15.85 11.77 14 35758 2468 46647822
Agitation 15.79 11.77 84 35688 55331 46594959
Wound haemorrhage 15.63 11.77 13 35759 2114 46648176
Haemodynamic instability 15.52 11.77 24 35748 7701 46642589
Dry skin 15.50 11.77 6 35766 41010 46609280
Balance disorder 15.40 11.77 16 35756 64505 46585785
Drug hypersensitivity 15.26 11.77 267 35505 243558 46406732
Post treatment Lyme disease syndrome 15.23 11.77 3 35769 6 46650284
Hypoaesthesia 15.10 11.77 44 35728 118825 46531465
Herpes zoster 14.92 11.77 18 35754 67854 46582436
Amoebic brain abscess 14.92 11.77 3 35769 7 46650283
Haematoma 14.91 11.77 56 35716 31816 46618474
Hepatic function abnormal 14.89 11.77 59 35713 34362 46615928
Depressed level of consciousness 14.87 11.77 74 35698 47495 46602795
Normochromic anaemia 14.77 11.77 6 35766 248 46650042
Purpura 14.76 11.77 27 35745 9931 46640359
Immune reconstitution inflammatory syndrome 14.73 11.77 20 35752 5705 46644585
Injection site pruritus 14.71 11.77 6 35766 39737 46610553
Neisseria infection 14.71 11.77 4 35768 45 46650245
Hemianopia 14.69 11.77 9 35763 904 46649386
Nephritis 14.50 11.77 12 35760 1938 46648352
Stress 14.45 11.77 11 35761 51540 46598750
Anoxia 14.43 11.77 6 35766 263 46650027
Coronary artery disease 14.40 11.77 4 35768 33748 46616542
Escherichia infection 14.38 11.77 28 35744 10789 46639501
Transverse sinus thrombosis 14.37 11.77 8 35764 672 46649618
Blister 14.36 11.77 70 35702 44561 46605729
Electrolyte imbalance 14.35 11.77 37 35735 17189 46633101
Ventricular dysfunction 14.27 11.77 14 35758 2818 46647472
Nocardiosis 14.26 11.77 11 35761 1606 46648684
Microangiopathic haemolytic anaemia 14.25 11.77 7 35765 455 46649835
Vitamin K deficiency 14.22 11.77 7 35765 457 46649833
Systemic inflammatory response syndrome 14.18 11.77 19 35753 5352 46644938
Blood pressure fluctuation 14.18 11.77 3 35769 30445 46619845
Dyspepsia 14.18 11.77 19 35753 68453 46581837
Stress cardiomyopathy 14.01 11.77 23 35749 7761 46642529
Hyperthyroidism 14.00 11.77 29 35743 11682 46638608
Clostridial infection 13.99 11.77 17 35755 4348 46645942
Lower respiratory tract infection 13.91 11.77 13 35759 55076 46595214
Hyperbilirubinaemia 13.85 11.77 27 35745 10411 46639879
Unmasking of previously unidentified disease 13.83 11.77 8 35764 723 46649567
Condition aggravated 13.81 11.77 264 35508 244788 46405502
Brain abscess 13.69 11.77 11 35761 1704 46648586
Skin test positive 13.66 11.77 8 35764 740 46649550
Anti-platelet antibody positive 13.66 11.77 4 35768 60 46650230
Endocarditis 13.65 11.77 18 35754 4994 46645296
Hyperthermia 13.52 11.77 23 35749 7991 46642299
Leukoencephalopathy 13.50 11.77 16 35756 3988 46646302
Hypertensive heart disease 13.47 11.77 13 35759 2565 46647725
Drug ineffective for unapproved indication 13.41 11.77 35 35737 16378 46633912
Dysmetria 13.29 11.77 6 35766 322 46649968
Thrombosis 13.28 11.77 14 35758 56055 46594235
Hypoxic-ischaemic encephalopathy 13.28 11.77 16 35756 4057 46646233
Chorioretinitis 13.24 11.77 6 35766 325 46649965
Hypoalbuminaemia 13.20 11.77 26 35746 10101 46640189
Ventricular fibrillation 13.20 11.77 28 35744 11468 46638822
Erysipelas 13.17 11.77 21 35751 6917 46643373
Septic embolus 13.16 11.77 8 35764 793 46649497
Sinusitis 13.12 11.77 53 35719 129715 46520575
Tracheobronchitis 13.07 11.77 9 35763 1103 46649187
Mixed liver injury 13.05 11.77 14 35758 3129 46647161
Chemotherapeutic drug level increased 12.96 11.77 5 35767 180 46650110
Vision blurred 12.89 11.77 26 35746 79682 46570608
Cerebral aspergillosis 12.85 11.77 6 35766 348 46649942
Pyelonephritis 12.80 11.77 33 35739 15324 46634966
Eyelid oedema 12.80 11.77 26 35746 10331 46639959
Splenomegaly 12.78 11.77 25 35747 9663 46640627
Myocarditis 12.78 11.77 22 35750 7717 46642573
Hyperpyrexia 12.70 11.77 13 35759 2753 46647537
CSF cell count increased 12.70 11.77 3 35769 18 46650272
Eosinophilic pneumonia acute 12.68 11.77 6 35766 359 46649931
Acute hepatic failure 12.65 11.77 32 35740 14689 46635601
Superior sagittal sinus thrombosis 12.65 11.77 8 35764 850 46649440
Muscle haemorrhage 12.48 11.77 14 35758 3290 46647000
Overlap syndrome 12.45 11.77 7 35765 600 46649690
Otitis media acute 12.30 11.77 8 35764 892 46649398
Upper respiratory tract infection bacterial 12.23 11.77 4 35768 88 46650202
Viral infection 12.15 11.77 4 35768 30231 46620059
Partial seizures 12.14 11.77 17 35755 4993 46645297
Cardiac tamponade 12.14 11.77 16 35756 4438 46645852
Sopor 12.04 11.77 38 35734 19790 46630500
Central nervous system vasculitis 11.95 11.77 8 35764 936 46649354
Pallor 11.93 11.77 42 35730 23124 46627166
Neutrophilia 11.91 11.77 13 35759 2964 46647326
CSF oligoclonal band present 11.90 11.77 4 35768 96 46650194
Hepatitis acute 11.83 11.77 22 35750 8192 46642098
Fluid retention 11.80 11.77 13 35759 51033 46599257
Intervertebral discitis 11.78 11.77 12 35760 2527 46647763

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Postrenal failure 302.74 12.01 77 38492 358 29913551
Drug reaction with eosinophilia and systemic symptoms 265.14 12.01 249 38320 28239 29885670
Jarisch-Herxheimer reaction 249.54 12.01 66 38503 368 29913541
Off label use 179.82 12.01 714 37855 248576 29665333
Rash maculo-papular 163.28 12.01 182 38387 25236 29888673
Cholelithiasis 147.73 12.01 155 38414 20070 29893839
Acute kidney injury 145.49 12.01 716 37853 273126 29640783
Eosinophilia 139.45 12.01 157 38412 22003 29891906
Pseudocholelithiasis 135.76 12.01 24 38545 0 29913909
Hepatocellular injury 131.37 12.01 163 38406 25308 29888601
Acute generalised exanthematous pustulosis 130.18 12.01 87 38482 6011 29907898
Pyrexia 128.28 12.01 729 37840 293760 29620149
Fatigue 125.77 12.01 137 38432 320536 29593373
Cholestasis 119.68 12.01 154 38415 24796 29889113
Anaphylactic shock 116.30 12.01 115 38454 13878 29900031
Hypertransaminasaemia 114.50 12.01 68 38501 3817 29910092
Death 114.08 12.01 178 38391 357105 29556804
Toxic encephalopathy 106.26 12.01 69 38500 4540 29909369
Hepatitis 104.11 12.01 136 38433 22220 29891689
Toxic epidermal necrolysis 100.94 12.01 120 38449 17820 29896089
Ureterolithiasis 99.33 12.01 48 38521 1771 29912138
Recalled product administered 91.88 12.01 30 38539 378 29913531
Pathogen resistance 90.87 12.01 80 38489 8330 29905579
Product dose omission issue 85.99 12.01 9 38560 91622 29822287
Long QT syndrome 85.29 12.01 47 38522 2286 29911623
Agranulocytosis 81.91 12.01 120 38449 21822 29892087
Drug abuse 79.81 12.01 7 38562 82065 29831844
Anaphylactic reaction 79.48 12.01 135 38434 27847 29886062
Drug-induced liver injury 78.92 12.01 116 38453 21158 29892751
Depression 77.32 12.01 12 38557 90425 29823484
Alanine aminotransferase increased 75.80 12.01 239 38330 74037 29839872
Nocardiosis 75.44 12.01 50 38519 3405 29910504
Haemolytic anaemia 71.79 12.01 76 38493 9934 29903975
Hydronephrosis 71.27 12.01 72 38497 8911 29904998
Fall 70.75 12.01 78 38491 181794 29732115
Myocardial infarction 70.38 12.01 37 38532 125588 29788321
Brain abscess 68.93 12.01 43 38526 2638 29911271
Septic shock 68.90 12.01 209 38360 63398 29850511
Factor V inhibition 68.53 12.01 20 38549 168 29913741
Dizziness 65.98 12.01 93 38476 194816 29719093
Clostridium difficile colitis 63.07 12.01 80 38489 12688 29901221
Haemolysis 63.01 12.01 61 38508 7170 29906739
Immune reconstitution inflammatory syndrome 61.57 12.01 67 38502 9034 29904875
COVID-19 pneumonia 58.93 12.01 48 38521 4492 29909417
Tubulointerstitial nephritis 58.49 12.01 92 38477 17799 29896110
Multiple organ dysfunction syndrome 58.19 12.01 197 38372 63290 29850619
Pruritus 57.42 12.01 302 38267 117902 29796007
Weight increased 55.53 12.01 14 38555 74899 29839010
Disseminated intravascular coagulation 47.82 12.01 95 38474 22076 29891833
Cerebrovascular accident 47.60 12.01 24 38545 83453 29830456
Respiratory failure 47.40 12.01 255 38314 100387 29813522
Appendicolith 46.43 12.01 23 38546 896 29913013
Electrocardiogram QT prolonged 45.79 12.01 125 38444 35710 29878199
Anuria 45.30 12.01 61 38508 10255 29903654
Transaminases increased 45.27 12.01 96 38473 23361 29890548
Stevens-Johnson syndrome 45.02 12.01 81 38488 17475 29896434
Inflammatory marker increased 44.13 12.01 35 38534 3153 29910756
Ureteral disorder 43.42 12.01 14 38555 169 29913740
Insomnia 42.10 12.01 35 38534 93301 29820608
Pain 41.82 12.01 101 38468 172540 29741369
Klebsiella infection 40.27 12.01 47 38522 6840 29907069
Thrombocytopenia 39.68 12.01 307 38262 136737 29777172
Blood glucose increased 39.32 12.01 15 38554 61515 29852394
Hepatitis toxic 37.88 12.01 27 38542 2070 29911839
COVID-19 37.83 12.01 76 38493 17802 29896107
Flank pain 36.86 12.01 42 38527 5956 29907953
Meningitis bacterial 36.54 12.01 21 38548 1108 29912801
Torsade de pointes 35.43 12.01 45 38524 7145 29906764
Urticaria 34.81 12.01 151 38418 54455 29859454
Choreoathetosis 34.47 12.01 19 38550 924 29912985
Anxiety 34.38 12.01 39 38530 89832 29824077
Joint swelling 34.34 12.01 9 38560 46937 29866972
Neutropenia 33.95 12.01 282 38287 128258 29785651
Rash morbilliform 33.63 12.01 27 38542 2475 29911434
Hospitalisation 33.38 12.01 8 38561 44311 29869598
Psoriasis 33.37 12.01 7 38562 42499 29871410
Acute respiratory distress syndrome 33.15 12.01 85 38484 23387 29890522
Liver function test increased 33.01 12.01 55 38514 11161 29902748
Liver injury 32.81 12.01 58 38511 12342 29901567
Portal fibrosis 32.52 12.01 14 38555 393 29913516
Toxic skin eruption 32.40 12.01 54 38515 10961 29902948
Acute hepatic failure 32.17 12.01 56 38513 11771 29902138
Trichosporon infection 31.98 12.01 16 38553 637 29913272
Cardiac failure congestive 31.89 12.01 37 38532 84370 29829539
Product use in unapproved indication 31.52 12.01 182 38387 73511 29840398
Alcohol intolerance 31.47 12.01 14 38555 426 29913483
Procalcitonin increased 31.47 12.01 19 38550 1099 29912810
Aspartate aminotransferase increased 31.40 12.01 163 38406 63259 29850650
Cardiogenic shock 31.37 12.01 68 38501 16793 29897116
Toxicity to various agents 31.20 12.01 120 38449 177063 29736846
Asthenia 31.10 12.01 163 38406 221127 29692782
Abdominal discomfort 31.00 12.01 12 38557 48779 29865130
Sphincter of Oddi dysfunction 30.84 12.01 10 38559 123 29913786
Hepatitis cholestatic 30.75 12.01 44 38525 7828 29906081
Hepatic enzyme increased 30.72 12.01 104 38465 33390 29880519
Crying 30.68 12.01 37 38532 5572 29908337
Drug resistance 30.63 12.01 75 38494 20058 29893851
Hepatomegaly 30.55 12.01 50 38519 9997 29903912
Fixed eruption 30.46 12.01 19 38550 1165 29912744
Rash 30.45 12.01 379 38190 191510 29722399
Pain in extremity 30.36 12.01 60 38509 110161 29803748
Malignant mesenteric neoplasm 30.33 12.01 8 38561 44 29913865
Hyperferritinaemia 30.16 12.01 13 38556 366 29913543
Antimicrobial susceptibility test resistant 29.60 12.01 10 38559 141 29913768
Condition aggravated 29.52 12.01 289 38280 137577 29776332
Leukocytosis 29.48 12.01 77 38492 21425 29892484
Cyanosis 29.25 12.01 54 38515 11881 29902028
Coronary artery disease 28.77 12.01 14 38555 49698 29864211
Erythema 28.52 12.01 184 38385 77267 29836642
Neurotoxicity 27.84 12.01 56 38513 13126 29900783
Pleocytosis 27.43 12.01 13 38556 459 29913450
Respiratory distress 27.31 12.01 99 38470 32873 29881036
Enterobacter infection 27.14 12.01 22 38547 2044 29911865
Jejunal ulcer perforation 27.12 12.01 8 38561 70 29913839
Hypertension 27.04 12.01 74 38495 121280 29792629
Hepatitis acute 26.80 12.01 39 38530 7044 29906865
Metastases to stomach 26.73 12.01 8 38561 74 29913835
Intentional overdose 26.68 12.01 10 38559 41471 29872438
Pseudomembranous colitis 26.51 12.01 25 38544 2843 29911066
Janeway lesion 26.44 12.01 6 38563 15 29913894
Cerebral cyst 26.42 12.01 10 38559 199 29913710
Suicidal ideation 26.27 12.01 7 38562 36107 29877802
Feeling abnormal 25.93 12.01 21 38548 56735 29857174
Weight decreased 25.42 12.01 104 38465 150817 29763092
Cardiac disorder 25.03 12.01 10 38559 39883 29874026
Bile duct stone 24.99 12.01 22 38547 2289 29911620
Nausea 24.69 12.01 254 38315 296703 29617206
Bronchopulmonary aspergillosis 24.54 12.01 51 38518 12233 29901676
Hypoxia 24.38 12.01 124 38445 47730 29866179
Drug intolerance 24.37 12.01 14 38555 45277 29868632
Drug interaction 24.27 12.01 376 38193 199192 29714717
Drug effective for unapproved indication 24.22 12.01 16 38553 1083 29912826
Tachypnoea 24.14 12.01 57 38512 14895 29899014
Endocarditis 23.93 12.01 34 38535 6009 29907900
Muscle abscess 23.86 12.01 12 38557 483 29913426
Encephalitis 23.72 12.01 35 38534 6401 29907508
Haemophagocytic lymphohistiocytosis 23.62 12.01 44 38525 9747 29904162
Dehydration 23.49 12.01 81 38488 123458 29790451
Tissue infiltration 23.27 12.01 7 38562 66 29913843
Omental necrosis 23.23 12.01 6 38563 30 29913879
Arthralgia 23.23 12.01 93 38476 135698 29778211
Eastern Cooperative Oncology Group performance status 23.23 12.01 6 38563 30 29913879
Jaundice 23.17 12.01 93 38476 32393 29881516
Coagulopathy 23.12 12.01 64 38505 18423 29895486
Malaise 22.86 12.01 124 38445 166838 29747071
Corynebacterium infection 22.83 12.01 11 38558 403 29913506
Muscle spasms 22.82 12.01 30 38539 64808 29849101
Pneumonia bacterial 22.36 12.01 42 38527 9361 29904548
Blood alkaline phosphatase increased 22.34 12.01 90 38479 31397 29882512
Diarrhoea 22.29 12.01 300 38269 333803 29580106
Constipation 22.16 12.01 73 38496 112833 29801076
Nasopharyngitis 22.00 12.01 26 38543 58823 29855086
Inappropriate schedule of product administration 21.78 12.01 12 38557 39716 29874193
Coagulation factor decreased 21.60 12.01 7 38562 86 29913823
Hepatic function abnormal 21.59 12.01 109 38460 41836 29872073
Splenomegaly 21.34 12.01 51 38518 13429 29900480
Liver transplant failure 21.03 12.01 7 38562 94 29913815
Headache 20.98 12.01 143 38426 182163 29731746
Angina pectoris 20.95 12.01 6 38563 29512 29884397
Appendicitis 20.64 12.01 32 38537 6112 29907797
Serum sickness-like reaction 20.63 12.01 7 38562 100 29913809
Morganella infection 20.54 12.01 10 38559 375 29913534
Therapeutic product effect decreased 20.47 12.01 6 38563 29070 29884839
Chest pain 20.47 12.01 80 38489 117547 29796362
Kounis syndrome 20.28 12.01 17 38552 1656 29912253
Calculus urinary 19.87 12.01 15 38554 1256 29912653
Escherichia infection 19.64 12.01 32 38537 6373 29907536
Pulmonary physical examination abnormal 19.52 12.01 5 38564 24 29913885
Contusion 19.36 12.01 8 38561 31272 29882637
Osteomyelitis fungal 19.33 12.01 8 38561 203 29913706
Acute respiratory failure 19.23 12.01 75 38494 25775 29888134
Interleukin-2 receptor increased 19.20 12.01 7 38562 125 29913784
Red blood cell schistocytes present 19.17 12.01 9 38560 311 29913598
Erythema nodosum 18.95 12.01 13 38556 937 29912972
Vascular purpura 18.89 12.01 16 38553 1581 29912328
Cholangitis 18.74 12.01 35 38534 7767 29906142
Antinuclear antibody negative 18.59 12.01 5 38564 30 29913879
Mucormycosis 18.49 12.01 28 38541 5240 29908669
Nail bed bleeding 18.45 12.01 5 38564 31 29913878
Infective chondritis 18.24 12.01 4 38565 8 29913901
Clostridium difficile infection 18.14 12.01 53 38516 15730 29898179
Prothrombin time ratio decreased 18.09 12.01 9 38560 354 29913555
Lymphopenia 17.90 12.01 47 38522 13116 29900793
Faeces pale 17.88 12.01 15 38554 1462 29912447
Wrong technique in product usage process 17.68 12.01 9 38560 31146 29882763
Peritoneal dialysis 17.65 12.01 10 38559 513 29913396
Encephalopathy 17.50 12.01 85 38484 32120 29881789
Drug eruption 17.48 12.01 56 38513 17470 29896439
Chondrocalcinosis 17.46 12.01 8 38561 261 29913648
Dry mouth 17.45 12.01 4 38565 22846 29891063
Diabetes mellitus 17.31 12.01 17 38552 41848 29872061
Gait disturbance 17.09 12.01 45 38524 74732 29839177
Gamma-glutamyltransferase increased 17.06 12.01 79 38490 29271 29884638
ADAMTS13 activity decreased 17.01 12.01 6 38563 97 29913812
Overdose 16.91 12.01 54 38515 84283 29829626
Intentional product misuse 16.89 12.01 12 38557 34655 29879254
Infective spondylitis 16.72 12.01 7 38562 183 29913726
Hypofibrinogenaemia 16.48 12.01 15 38554 1630 29912279
Red blood cell sedimentation rate decreased 16.36 12.01 5 38564 50 29913859
Carotid artery insufficiency 16.21 12.01 4 38565 16 29913893
Peripheral swelling 16.16 12.01 34 38535 61040 29852869
Malignant neoplasm progression 16.14 12.01 44 38525 72243 29841666
Dermatitis exfoliative generalised 16.10 12.01 19 38550 2796 29911113
Balance disorder 16.05 12.01 14 38555 36479 29877430
Drug ineffective for unapproved indication 15.98 12.01 40 38529 10840 29903069
Disseminated cryptococcosis 15.98 12.01 12 38557 997 29912912
Henoch-Schonlein purpura 15.85 12.01 14 38555 1463 29912446
Coronavirus infection 15.84 12.01 21 38548 3477 29910432
Erythema annulare 15.83 12.01 4 38565 18 29913891
Human T-cell lymphotropic virus type I infection 15.83 12.01 4 38565 18 29913891
Whipple's disease 15.83 12.01 4 38565 18 29913891
Erythema multiforme 15.77 12.01 33 38536 7952 29905957
Hyperthermia 15.76 12.01 38 38531 10061 29903848
Drug dependence 15.73 12.01 4 38565 21291 29892618
Vitamin B1 deficiency 15.67 12.01 7 38562 215 29913694
Mobility decreased 15.53 12.01 7 38562 25992 29887917
Memory impairment 15.48 12.01 15 38554 37159 29876750
Dermatitis bullous 15.44 12.01 28 38541 6076 29907833
Hypercreatininaemia 15.42 12.01 9 38560 489 29913420
Amnesia 15.41 12.01 6 38563 24315 29889594
Strongyloidiasis 15.39 12.01 17 38552 2329 29911580
Vanishing bile duct syndrome 15.39 12.01 10 38559 658 29913251
Candida infection 15.24 12.01 49 38520 15313 29898596
Syncope 15.24 12.01 57 38512 84846 29829063
Pneumococcal sepsis 15.11 12.01 10 38559 679 29913230
Vision blurred 15.07 12.01 19 38550 41797 29872112
Orthostatic hypotension 15.06 12.01 6 38563 23973 29889936
Suicide attempt 15.06 12.01 15 38554 36682 29877227
Prostate cancer 15.03 12.01 6 38563 23951 29889958
Vitamin A deficiency 15.02 12.01 4 38565 23 29913886
Altered state of consciousness 14.99 12.01 58 38511 19861 29894048
Neuropathy peripheral 14.93 12.01 44 38525 70431 29843478
Metastases to heart 14.85 12.01 6 38563 143 29913766
Fistula discharge 14.84 12.01 8 38561 372 29913537
Transient ischaemic attack 14.72 12.01 7 38562 25193 29888716
Renal papillary necrosis 14.70 12.01 6 38563 147 29913762
Hypocoagulable state 14.69 12.01 11 38558 910 29912999
Leukopenia 14.68 12.01 123 38446 56036 29857873
Gastrooesophageal reflux disease 14.65 12.01 12 38557 32243 29881666
Bronchial haemorrhage 14.60 12.01 10 38559 719 29913190
Cataract 14.49 12.01 5 38564 21830 29892079
Meningitis candida 14.45 12.01 5 38564 76 29913833
Bronchopleural fistula 14.39 12.01 8 38561 396 29913513
Tick-borne viral encephalitis 14.34 12.01 4 38565 28 29913881
Low birth weight baby 14.27 12.01 27 38542 6049 29907860
Rash erythematous 14.23 12.01 62 38507 22390 29891519
Erectile dysfunction 14.16 12.01 3 38566 18099 29895810
Coagulation factor V level decreased 14.15 12.01 7 38562 272 29913637
Incorrect dose administered 14.13 12.01 12 38557 31674 29882235
Haematuria traumatic 14.12 12.01 6 38563 163 29913746
Aggression 14.12 12.01 16 38553 36891 29877018
Drug withdrawal syndrome 14.10 12.01 4 38565 19805 29894104
Neoplasm progression 14.08 12.01 3 38566 18020 29895889
Local anaesthetic systemic toxicity 13.98 12.01 6 38563 167 29913742
Hepatitis fulminant 13.90 12.01 21 38548 3920 29909989
No reaction on previous exposure to drug 13.78 12.01 5 38564 88 29913821
Ureteric obstruction 13.75 12.01 12 38557 1234 29912675
Hypoaesthesia 13.68 12.01 31 38538 54199 29859710
Mechanical urticaria 13.68 12.01 5 38564 90 29913819
COVID-19 treatment 13.67 12.01 7 38562 293 29913616
Influenza like illness 13.65 12.01 8 38561 25597 29888312
Organic brain syndrome 13.62 12.01 5 38564 91 29913818
Gonorrhoea 13.57 12.01 5 38564 92 29913817
Small intestine carcinoma 13.50 12.01 8 38561 447 29913462
Autoimmune haemolytic anaemia 13.44 12.01 21 38548 4038 29909871
Neuralgic amyotrophy 13.41 12.01 6 38563 185 29913724
Stomatitis 13.37 12.01 17 38552 37262 29876647
Haemorrhoids thrombosed 13.29 12.01 6 38563 189 29913720
Ocular icterus 13.27 12.01 18 38551 3046 29910863
Gallbladder enlargement 13.21 12.01 10 38559 841 29913068
Shock haemorrhagic 13.18 12.01 35 38534 9830 29904079
Unevaluable event 13.03 12.01 13 38556 31772 29882137
Cholestatic liver injury 13.00 12.01 13 38556 1588 29912321
Hypovolaemic shock 13.00 12.01 27 38542 6473 29907436
Face oedema 12.97 12.01 38 38531 11296 29902613
Tuberculosis of genitourinary system 12.91 12.01 4 38565 42 29913867
Blood cholesterol increased 12.90 12.01 3 38566 16967 29896942
Intracranial pressure increased 12.89 12.01 19 38550 3471 29910438
Lung abscess 12.82 12.01 16 38553 2495 29911414
Osteonecrosis of jaw 12.82 12.01 4 38565 18614 29895295
Sleep apnoea syndrome 12.77 12.01 3 38566 16854 29897055
Listeriosis 12.75 12.01 10 38559 886 29913023
Megacolon 12.63 12.01 13 38556 1644 29912265
Idiopathic orbital inflammation 12.58 12.01 3 38566 10 29913899
Urticarial vasculitis 12.58 12.01 4 38565 46 29913863
Loss of personal independence in daily activities 12.55 12.01 6 38563 21529 29892380
Status epilepticus 12.55 12.01 37 38532 11035 29902874
Procalcitonin abnormal 12.54 12.01 5 38564 115 29913794
Decreased appetite 12.50 12.01 128 38441 149782 29764127
Pulmonary necrosis 12.47 12.01 7 38562 353 29913556
Device related sepsis 12.45 12.01 15 38554 2257 29911652
Sphingomonas paucimobilis infection 12.43 12.01 4 38565 48 29913861
Distal intestinal obstruction syndrome 12.38 12.01 7 38562 358 29913551
Polycystic liver disease 12.35 12.01 4 38565 49 29913860
Haemodynamic instability 12.34 12.01 30 38539 7985 29905924
Dyspnoea 12.33 12.01 331 38238 332964 29580945
Musculoskeletal pain 12.29 12.01 13 38556 30927 29882982
Recalled product 12.27 12.01 7 38562 364 29913545
Acidosis 12.23 12.01 35 38534 10266 29903643
Pulmonary function test 12.16 12.01 3 38566 12 29913897
Normocytic anaemia 12.10 12.01 12 38557 1452 29912457
Crystalluria 12.06 12.01 7 38562 376 29913533

Pharmacologic Action:

SourceCodeDescription
ATC J01DD04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
ATC J01DD54 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
ATC J01DD63 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:35625 beta-lactamase inhibitors
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:88188 allergenic drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Gonococcal meningitis indication 151004
Streptococcal meningitis indication 4510004 DOID:11574
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Staphylococcal meningitis indication 12166008
Gonorrhea indication 15628003 DOID:7551
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Streptococcal septicemia indication 29577008
Acute gonococcal urethritis indication 29864006
Pneumonia due to Streptococcus indication 34020007
Gonorrhea of rectum indication 42746002
Gonococcal infection of joint indication 44743006
Bacterial arthritis indication 48245008
Salmonella septicemia indication 49786009
Lower respiratory tract infection indication 50417007
Pneumococcal meningitis indication 51169003
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Gonococcal endocarditis indication 61048000
Acute gonococcal endometritis indication 65295003 DOID:7527
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Bacterial infection due to Serratia indication 71120004
Rhinoscleroma indication 72409005 DOID:11336
Gonorrhea of pharynx indication 74372003
Endometritis indication 78623009 DOID:1002
Bacterial meningitis indication 95883001 DOID:9470
Infection of bone indication 111253001
Staphylococcal septicemia indication 111821004
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Meningococcal meningitis indication 192644005
Escherichia coli meningitis indication 192655005
Proteus pneumonia indication 195888009
Chancroid indication 266143009 DOID:13778
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Infectious disorder of joint indication 363162000
Meningitis due to Klebsiella mobilis indication 420585007
Peptostreptococcus infection indication 135341000119101
Klebsiella Pneumoniae Osteomyelitis indication
Inflammatory Disease of Female Pelvic Organs indication
Proteus Mirabilis Osteomyelitis indication
Peptostreptococcus Peritonitis indication
Enterobacter Pneumonia indication
Proteus Joint Infection indication
Haemophilus Septic Arthritis indication
Skin and Skin Structure Serratia Infection indication
E. Coli Peritonitis indication
Prevention of Perioperative Infection indication
Haemophilus Influenzae Type B Infections indication
Adult Gonococcal Conjunctivitis indication
E. Coli Septic Arthritis indication
Haemophilus Septicemia indication
Disseminated Gonococcal Infection indication
Klebsiella Pneumoniae Peritonitis indication
H. Influenzae Meningitis indication
Prevention of Meningococcal Meningitis indication
Gram-Negative Aerobic Bacillary Pneumonia indication
Skin and Skin Structure Proteus Infection indication
Haemophilus Osteomyelitis indication
Haemophilus Parainfluenzae Pneumonia indication
Enterobacter Osteomyelitis indication
Streptococcal Joint Infection indication
Pelvic Inflammatory Disease with Neisseria Gonorrhea indication
Klebsiella Joint Infection indication
EnterobacterJoint Infection indication
Skin and Skin Structure Morganella Morganii Infection indication
Streptococcus Osteomyelitis indication
E. Coli Joint Infection indication
E. Coli Osteomyelitis indication
Pyrexia of unknown origin off-label use 7520000
Lyme disease off-label use 23502006 DOID:11729
Lyme arthritis off-label use 33937009
Pseudotuberculosis off-label use 36753006
Lyme carditis off-label use 77863005
Infection by Yersinia enterocolitica off-label use 80960004
Ventilator-acquired pneumonia off-label use 429271009
Lyme Disease of the Central Nervous System off-label use
Sexual Transmitted Disease Exposure from Sexual Assault off-label use
Disorder of gallbladder contraindication 39621005 DOID:0060262
Acute nephropathy contraindication 58574008
Hemolytic anemia contraindication 61261009 DOID:583
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pseudomembranous enterocolitis contraindication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.65 acidic
pKa2 4.17 acidic
pKa3 13.31 acidic
pKa4 3.29 Basic
pKa5 0.93 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D-amino-acid oxidase Enzyme IC50 5 CHEMBL
Penicillin-binding protein 2 Enzyme INHIBITOR IC50 6.21 WOMBAT-PK CHEMBL
Penicillin-binding protein 1B Enzyme INHIBITOR IC50 5.74 WOMBAT-PK CHEMBL
Penicillin-binding protein 1A Enzyme INHIBITOR IC50 6.51 WOMBAT-PK CHEMBL
Peptidoglycan synthase FtsI Enzyme INHIBITOR IC50 6.14 WOMBAT-PK CHEMBL

External reference:

IDSource
4019667 VUID
N0000147759 NUI
D00924 KEGG_DRUG
104376-79-6 SECONDARY_CAS_RN
4017814 VANDF
4019667 VANDF
C0007561 UMLSCUI
CHEBI:29007 CHEBI
9F2 PDB_CHEM_ID
CHEMBL161 ChEMBL_ID
CHEMBL1200995 ChEMBL_ID
CHEMBL3183968 ChEMBL_ID
DB01212 DRUGBANK_ID
D002443 MESH_DESCRIPTOR_UI
5479530 PUBCHEM_CID
5326 IUPHAR_LIGAND_ID
4923 INN_ID
75J73V1629 UNII
203172 RXNORM
1314 MMSL
4387 MMSL
69782 MMSL
d00052 MMSL
002734 NDDF
004849 NDDF
19841008 SNOMEDCT_US
33440000 SNOMEDCT_US
372670001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9678 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 26 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9768 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 23 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9856 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 24 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9857 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 24 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9858 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 24 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9859 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 24 sections
CEFTRIAXONE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3153 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 26 sections
CEFTRIAXONE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3155 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 26 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0338-5002 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0338-5003 INJECTION, SOLUTION 2 g INTRAVENOUS ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7332 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7332 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7333 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 21 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7333 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 21 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7334 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 25 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7334 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 25 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7335 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7335 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7336 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 21 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7336 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 21 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7337 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7337 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7338 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7338 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3206 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 26 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3207 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 26 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3208 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3209 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3210 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 21695-202 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 23 sections